Migraine Headache: Updates and Future Developments

Parker E. Bohm, Fernando F. Stancampiano, Todd D. Rozen

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene–related peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine.

Original languageEnglish (US)
Pages (from-to)1648-1653
Number of pages6
JournalMayo Clinic proceedings
Issue number11
StatePublished - Nov 2018

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Migraine Headache: Updates and Future Developments'. Together they form a unique fingerprint.

Cite this